← Eichor
Condition: Hematological Malignancies B Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hematological Malignancies B

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Phase 1 · 1 location(s) · The Third Affiliated Hospital of Southern Medical University · NCT06758713Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematologi
Phase N/A · 5 location(s) · Medical University Innsbruck · NCT06821880In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
NA · 1 location(s) · Zhejiang Cancer Hospital · NCT07670949Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/Phase 2 · 6 location(s) · Daiichi Sankyo · NCT07220616B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide
Phase 1 · 1 location(s) · Mayo Clinic · NCT06191887Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07584889National Longitudinal Cohort of Hematological Diseases
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04645199GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Grit Biotechnology · NCT06948981The Study of ICP-248 in Patients With Mature B-cell Malignancies
Phase 1 · 22 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05728658Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Phase 1/Phase 2 · 3 location(s) · Ottawa Hospital Research Institute · NCT03765177Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Phase 2 · 1 location(s) · Chi Kong Li · NCT06462248HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 · 1 location(s) · University of Florida · NCT05800210MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT0691403764Cu-LLP2A for Imaging Hematologic Malignancies
EARLY_Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06636175The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NA · 1 location(s) · Hebei Senlang Biotechnology Inc., Ltd. · NCT05618041A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safe
Phase N/A · 9 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07185503Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.